Fox Run Management L.L.C. Acquires Shares of 4,413 Regeneron Pharmaceuticals, Inc. $REGN

Fox Run Management L.L.C. bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 4,413 shares of the biopharmaceutical company’s stock, valued at approximately $2,481,000. Regeneron Pharmaceuticals comprises about 0.4% of Fox Run Management L.L.C.’s investment portfolio, making the stock its 9th largest position.

Other large investors have also modified their holdings of the company. Osaic Holdings Inc. lifted its stake in Regeneron Pharmaceuticals by 55.2% during the second quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock worth $9,607,000 after purchasing an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of Regeneron Pharmaceuticals by 153.4% during the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after purchasing an additional 73,176 shares during the period. PGGM Investments lifted its position in shares of Regeneron Pharmaceuticals by 9.7% in the 3rd quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after buying an additional 8,187 shares during the last quarter. Rakuten Investment Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $33,121,000. Finally, Sound Shore Management Inc CT bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $64,677,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $772.19 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm has a market capitalization of $81.64 billion, a PE ratio of 18.58, a P/E/G ratio of 2.11 and a beta of 0.40. The company’s 50 day simple moving average is $770.19 and its 200 day simple moving average is $677.75. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the company posted $12.07 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Wall Street Zen cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Citigroup raised their price target on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $768.00 to $769.00 and gave the company an “equal weight” rating in a research report on Monday, February 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Finally, BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approves Dupixent (dupilumab) for allergic fungal rhinosinusitis (AFRS), adding a ninth U.S. indication and supported by Phase 3 data showing reduced nasal symptoms, steroid use and need for surgery — a commercial upside for the Dupixent franchise. Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
• Positive Sentiment: FDA has accepted the biologics license application for garetosmab under Priority Review for fibrodysplasia ossificans progressiva (FOP). If approved, this would add a high-value, rare-disease therapy to Regeneron’s portfolio and de-risk the late-stage pipeline. FDA Accepts Regeneron (REGN) BLA for Garetosmab Under Priority Review
• Positive Sentiment: Regeneron raised its quarterly dividend to $0.94 (from $0.88), signaling cash return to shareholders and confidence in cash flow generation. This supports shareholder yield and may attract income-focused investors. Regeneron Pharmaceuticals Director Sells $1,279,818.54 in Stock (MarketBeat item contains dividend info)
• Neutral Sentiment: Partner news — Tessera’s TSRA-196 (in vivo gene editing for AATD) received FDA Fast Track and Orphan Drug designations; the program is being developed jointly with Regeneron, which could broaden longer-term collaboration value but is early-stage. Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for TSRA-196
• Neutral Sentiment: Analyst and institutional activity mixed: a range of price-target moves and institutional inflows/outflows were reported — useful context for medium-term sentiment but not an immediate catalyst. Regeneron Pharmaceuticals price/analyst summary (MarketBeat)
• Negative Sentiment: Company director Huda Zoghbi sold 1,638 shares for roughly $1.28M, cutting her stake nearly in half. Large insider sales can be interpreted as a negative signal or simply personal liquidity — investors often view such filings as short-term selling pressure. Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $1,279,818.54 in Stock
• Negative Sentiment: Market commentary notes REGN is facing near-term resistance/profit-taking despite approvals and pipeline news — that likely explains today’s downward move as investors lock gains after the recent run-up. Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the sale, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the sale, the director owned 1,703 shares of the company’s stock, valued at $1,330,604.99. The trade was a 49.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,274 shares of company stock valued at $4,142,738 over the last 90 days. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.